Metabolon focuses efforts on MS (multiple sclerosis) biomarkers
This article was originally published in Clinica
Executive Summary
Aiming to improve the diagnosis and treatment of multiple sclerosis (MS), gene discovery company Metabolon has been awarded a contract from the US Centers for Disease Control and Prevention (CDC) to identify biomarkers for the disease.